Clinical Genomics closed $15M financing round for colorectal cancer recurrence blood test: 4 points

Listen
Text
  • Small
  • Medium
  • Large

Clinical Genomics recently closed a $15 million series A financing round.

Here are four points:

1. The funds will be used to advance commercialization of the company's two-gene blood test for post-surgical monitoring of colorectal cancer recurrence.

2. The blood test aims to detect tumor-specific methylated DNA biomarkers that leak from active lesions into the circulatory system.

3. The financing is being led by OneVentures, a venture capital firm.

4. Paul Kelly, MD, partner and managing director of OneVentures, will join Clinical Genomics' board of directors in connection with the financing.

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast